The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

Intratumoral immunotherapies aim at reducing local immunosuppression, as well as reinstating and enhancing systemic anticancer T-cell functions, without inducing side effects. LTX-315 is a first-in-class oncolytic peptide-based local immunotherapy that meets these criteria by inducing a type of mali...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Differ
Main Authors: Yamazaki, T, Pitt, J M, Vétizou, M, Marabelle, A, Flores, C, Rekdal, Ø, Kroemer, G, Zitvogel, L
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4987735/
https://ncbi.nlm.nih.gov/pubmed/27082453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2016.35
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados